TrialBlood2025

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.

Joshua F Zeidner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.